.

Click This

GSK Pays N717.5m Dividend As Shareholders Approve 1 for 4 Bonus


GlaxoSmithKline Consumer Nigeria Plc has declared a N717.5 million dividend for the 2014 financial year, just as shareholders of the company approved the one for four bonus shares proposed by its Board of Directors.In the year under review, the company recorded a turnover of N30.52 billion growing 5 per cent over the previous year.
Profit before tax at N2.75billion and profit after tax at N1.85 billion declined over the previous year by 36 per cent and 37 per cent respectively. Total assets grew from N26.2 billion to N27.96 billion during the year ended December, 2014.
Speaking at the 44th Annual General Meeting held in Lagos, Chairman, Board of Director, GSK, Mr. Edmund Onuzo, highlighted some of the challenges faced by its business in the year under review to include:
a drop in Nigeria’s crude oil production which was aggravated by the drop of crude oil prices; insecurity, especially the incessant violence in the Northern states and sporadic cases of kidnapping for ransom;
the Nigerian Stock Exchange ending year on a negative note as a result of collapse in world oil prices; among others.
According to him “While operating expenses were well managed, the company recorded an exchange loss of N893 million as a result of the naira devaluation by the Central Bank of Nigeria, CBN in the first quarter of 2014. Furthermore, an increase in cost of goods sold of N1.234 billion as a result of the sale of brands by the GSK group to Lucozade Ribena Suntory, added to the decline in profit.”
Onuzo noted that another major challenge encountered in the year was the healthcare sector outbreak of the dreaded Ebola Virus Disease (EVD) and industrial actions by health workers due to alleged insincerity on the part of government. According to him “The incidence of counterfeits and parallel imports continues to be a big challenge to the business and our ability to ensure we deliver products of value, especially the pharmaceuticals to our consuming public.
During the year GSK continued to work with the regulatory agencies including NAFDAC and customs to stem the unfortunate menace of counterfeit fake and parallel imports.” Onuzo however said that for the company to be successful, it must confront and overcome identified risks to its growth and profitability in the next 12 months.
He said “Our winning strategy for the coming years must include a strategic re-design of our Route to Market (RTM) with portfolio focus to build momentum behind drinks, invest in key SKUs (PET, 150ml), drive deeper and wider penetration and strengthen the non-drinks portfolio.
“The company would also focus on a commercial model ensuring distributor margin and investment aligned to support growth. We must as a mater priority continue to invest in talent to build demand generation and efficiency, deepen our demand planning capability and route to market expertise.”
“We would continue to strengthen our customer marketing intelligence and to build strategic alliance with our distributors pan Nigeria to ensure reach and penetration” he added


#Providence_Obuh #Brand_NewsNigeria

No comments:

Post a Comment